Takeda Pharmaceutical Company Ltd

MP Nigdelis received honoraria from RG Ärztefortbildung GmbH and travel grants from Organon and Gedeon Richter. M Doerk received travel grants from Gedeon Richter, Organon, and Eisai, and is a member of DGGG, AGE, and Deutsche Gesellschaft für Senologie. S Burghaus received honoraria from FOMF and is a member of DGGG, AGEM, AGE, Stiftung Endometriose Forschung, AGUB, AGO, and DKK. M Sillem, CEO of EuroEndoCert Gmbh, received payments from Bayer, Gedeon Richter, Hologic, and EndoHealth. B Haj Hamoud received travel grants from Gedeon Richter, Astrazeneca, Johnson & Johnson, and Storz, and is a member of DGGG, AGE, and Stiftung Endometriose Forschung. EF Solomayer receives grants from the University of Saarland, Storz, and Erbe, and fees from Roche, Pfizer, Celgene, Amgen, Astra Zeneca, Esai, Johnson & Johnson, Novartis, Tesaro, Teva, Medac GmbH, MSD, Vifor, Gedeon Richter, Takeda, and AGE, among others. GL Olmes received grants from AstraZeneca, Universitätsklinikum Freiburg, and RG Ärztefortbildung GmbH, and is a member of DGGG, AGE, and AGEM, with scientific collaboration with Karl Stotz.

Tempus AI expands collaboration with Takeda, leveraging multimodal real-world datasets and biological modeling to advance Takeda's oncology research, potentially leading to new cancer treatments.

Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to the ARTEMIS-UC trial. The study incorporated a predictive biomarker for response, showing significant clinical remission, endoscopic improvement, and clinical response in patients on tulisokibart compared to placebo. A phase 3 program is planned to confirm these results.

IBD, including Crohn's disease and ulcerative colitis, lacks reliable predictors for treatment response. This Research Topic aims to identify and validate novel biomarkers to optimize personalized therapy, focusing on genetic, microbial, transcriptomic, and immunologic data.

Vietnam's healthcare sector aims to align with global R&D trends, emphasizing innovation in mindset, technology, access, and investment. The focus shifts from pharmaceuticals to self-repair mechanisms, leveraging AI and biotechnology. Amendments to the 2016 Law on Pharmacy and $20 billion in economic contribution within 15 years are targeted, with startups playing a crucial role.

Avantor enters 10-year virtual power purchase agreement for 25GWh of renewable energy annually from 2026, supporting three new solar projects in Spain. The agreement reflects Avantor's commitment to reducing greenhouse gas emissions and lowering supply chain costs.

Brian Johnson, VP, R&D Technology at Takeda, discusses the potential of generative AI to connect disparate health datasets, emphasizing the need for prompt engineers and cautioning against widening health equity gaps. He highlights the importance of improving datasets for people of color through initiatives like Acclinate and Inside Edge Consulting.

Illumina welcomed the ECJ's judgment on GRAIL acquisition; Moffitt Cancer Center and AstraZeneca collaborate on cell therapies; Ginkgo Bioworks introduced Ginkgo Automation; UTHealth Houston and OpenAI integrate AI in healthcare; 10x Genomics' platforms used in glioblastoma research; Generate:Biomedicines and Novartis collaborate on protein therapeutics; Firefly Neuroscience advances AI in neuroscience drug development; Scale Bio partners with CZI in the 100 Million Cell Challenge; Oracle launches CancerMPact Treatment Architecture Trends; Verseon's VersAI outperforms Google's AI; MilliporeSigma introduces Mobius ADC Reactor; Gilead and Genesis Therapeutics collaborate on small molecule therapies; Primrose Bio and ExPLoRNA partner on mRNA medicines; UC College of Medicine and Cincinnati Children’s Hospital find new drug discovery methods.

Generative AI, paired with data analytics, accelerates project execution for companies, as highlighted in the 2024 MIT Sloan Master of Business Analytics Capstone Project. This trend contrasts with 'legacy machine learning,' which enables precision but lacks speed. Projects involving life sciences, insurance, telecommunications, and retail sectors demonstrate generative AI's potential to expedite drug development, customer response, and internal communication. Additionally, the integration of generative AI aims to improve workforce management and accuracy in various business processes.

Takeda receives approval for FRUZAQLA, a novel targeted therapy for metastatic colorectal cancer in Japan, based on the positive results of the global Phase 3 FRESCO-2 trial.